Neuraminidase inhibitors for influenza: A review and public health perspective in the aftermath of the 2009 pandemic

Influenza and other Respiratory Viruses

Volumn 7, Issue 1 SUPPL.1, 2013, Pages 14-24

  Beck, Charles R ^a   Sokal, Rachel ^b   Arunachalam, Nachiappan ^c   Puleston, Richard ^a   Cichowska, Anna ^c   Kessel, Anthony ^c   Zambon, Maria ^c   Nguyen Van Tam, Jonathan S ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Public Health Directorate   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Clinical effectiveness; Neuraminidase inhibitors; Pandemic influenza; Seasonal influenza

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ALLERGIC REACTION; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CAUSE OF DEATH; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EARLY INTERVENTION; FATIGUE; FLU LIKE SYNDROME; HEALTH IMPACT ASSESSMENT; HEPATOBILIARY DISEASE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INSOMNIA; LONG TERM CARE; MORTALITY; OBSERVATIONAL STUDY; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY FAILURE; RISK REDUCTION; SEASONAL INFLUENZA; SYMPTOM; VERTIGO;

ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PANDEMICS; POST-EXPOSURE PROPHYLAXIS; PUBLIC HEALTH; SEASONS;

EID: 84871845649     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12048     Document Type: Article

References (99)

1. Nguyen-Van-Tam JS. Zanamivir for influenza: a public health perspective. BMJ 1999; 319:655-656.
2. Boseley S. GPs told not to prescribe new flu drug. The Guardian. 1999. Available at: http://www.guardian.co.uk/uk/1999/oct/09/sarahboseley. (Accessed 30 November 2011).
3. BBC. NHS agenda for expensive drugs. 1999. Available at: http://news.bbc.co.uk/1/hi/health/413566.stm. (Accessed 30 November 2011).
4. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006; 194(Suppl.):S119-S126.
5. Godlee F. We want raw data, now. BMJ 2009; 339:b5405.
6. European Centre for Disease Prevention and Control. Public Health use of Influenza Antivirals During Influenza Pandemics. Stockholm; 2009.
7. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 168. Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza. London: National Institute for Health and Clinical Excellence; 2009.
8. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 158. Oseltamivir, Amantadine (review) and Zanamivir for the Prophylaxis of Influenza. London: National Institute for Health and Clinical Excellence; 2008.
9. Burch J, Paulden M, Conti S et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009; 13:1-265.
10. World Health Organization. Pandemic Influenza Preparedness and Response: A WHO Guidance Document. Geneva; 2009.
11. World Health Organization. Comparative Analysis of National Pandemic Influenza Preparedness Plans. Geneva; 2011.
12. Donner B, Bader-Weder S, Schwarz R et al. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf 2011; 20:532-543.
13. Atkins CY, Patel A, Taylor TH et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis 2011; 17:1591-1598.
14. Department of Health. Use of Antivirals in an Influenza Pandemic. London; 2011:1-317. Available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_125328.pdf.
15. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2, 3-dehydro-N-acetylneuraminic acid. Virology 1974; 58:457-463.
16. Palese P, Schulman JL, Bodo G, Meindl P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 1974; 59:490-498.
17. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976; 33:159-163.
18. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303:41-44.
19. von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
20. Kim CU, Lew W, Williams MA et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119:681-690.
21. Monto AS. Editorial commentary: viral susceptibility and the choice of influenza antivirals. Clin Infect Dis 2008; 47:346-348.
22. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44(Suppl. B):23-29.
23. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother 2010; 65(Suppl. 2):ii11-ii24.
24. DataPharm. Summary of Product Characteristics - Tamiflu 75mg hard capsule. The electronic Medicines Compendium. 2011. Available at: http://www.medicines.org.uk/emc/medicine/10446/SPC/. (Accessed 31 December 2011).
25. GlaxoSmithKline UK. Relenza 5mg/dose inhalation - Summary of Product Characteristics (SPC) - electronic Medicines Compendium (eMC). 2011. Available at: http://www.medicines.org.uk/EMC/medicine/2608/SPC/Relenza+5mg+dose+inhalation+powder. (Accessed 14 December 2011).
26. Roche Products Limited. Tamiflu 75mg hard capsule - Summary of Product Characteristics (SPC) - electronic Medicines Compendium (eMC). 2011. Available at: http://www.medicines.org.uk/EMC/medicine/10446/SPC/Tamiflu+75mg+hard+capsule. (Accessed 14 December 2011).
27. Singh S, Barghoorn J, Bagdonas A et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig 2003; 23:561-569.
28. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161:212-217.
29. Deng W, Li Q, Zhong N. A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients. Zhonghua Yi Xue Za Zhi. 2004; 84:2132-2136.
30. Hedrick JA, Barzilai A, Behre U et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000; 19:410-417.
31. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20:127-133.
32. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21:761-768.
33. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007; 23:523-531.
34. Lee N, Chan PKS, Choi KW et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501-508.
35. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf 2004; 13:227-237.
36. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med. 2008; 10:131.
37. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin 2007; 23:2961-2970.
38. Casscells SW, Granger E, Kress AM et al. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes 2009; 2:108-115.
39. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008; 9:151-161.
40. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther 2007; 29:2246-2255.
41. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology 2009; 113:98-107.
42. Chemaly RF, Ghosh S, Bodey GP et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006; 85:278-287.
43. Chemaly RF, Torres HA, Aguilera EA et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964-967.
44. McGeer A, Green KA, Plevneshi A et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-1575.
45. Lee N, Choi KW, Chan PKS et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510-515.
46. Hanshaoworakul W, Simmerman JM, Narueponjirakul U et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009; 4:e6051.
47. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124:170-178.
48. Tappenden P, Jackson R, Cooper K et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009; 13:1-246.
49. Monto AS, Robinson DP, Herlocher ML et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-35.
50. Centers for Disease Control and Prevention. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep 1998; 47:196-200.
51. GlaxoSmithKline Pharmaceuticals. Drugs for the prophylaxis of influenza - review of zanamivir. 2007.
52. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza - placebo-controlled double-blind multicenter phase III trial. Kansenshōgaku Zasshi 2000; 74:1062-1076.
53. Hayden FG, Atmar RL, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-1343.
54. LaForce C, Man CY, Henderson FW et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007; 29:1579-1590.
55. Peters PH, Gravenstein S, Norwood P et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-1031.
56. Halloran ME, Hayden FG, Yang Y, Longini IM, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007; 165:212-221.
57. Ng S, Cowling BJ, Fang VJ et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 2010; 50:707-714.
58. Shinjoh M, Sato S, Sugaya N et al. Effect of post-exposure prophylaxis with oseltamivir for those in contacts with influenza patients in pediatric wards. Kansenshōgaku Zasshi. 2004; 78:262-269.
59. Ambrozaitis A, Gravenstein S, van Essen GA et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005; 6:367-374.
60. Hirji Z, O'Grady S, Bonham J et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population. Infect Control Hosp Epidemiol 2002; 23:604-608.
61. Bush KA, McAnulty J, McPhie K et al. Antiviral prophylaxis in the management of an influenza outbreak in an aged care facility. Commun Dis Intell 2004; 28:396-400.
62. Chik KW, Li CK, Chan PKS et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J 2004; 10:103-106.
63. World Health Organization. Evolution of a pandemic 2010.
64. NHS Flu Resilience Team. Swine flu pandemic: from containment to treatment. Guidance for the NHS. 2009.
65. European Centre for Disease Prevention and Control. The 2009 A(H1N1) pandemic in Europe Stockholm; 2010.
66. World Health Organization. H1N1 in post-pandemic period. Media statement. 2010. Available at: http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html.
67. Boutolleau D, Houhou N, Deback C, Agut H, Brun-Vezinet F. Detection of pandemic (H1N1) 2009 virus in patients treated with oseltamivir. Emerg Infect Dis 2010; 16:351-352.
68. Cao B, Li X-W, Mao Y et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507-2517.
69. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
70. To KKW, Chan K-H, Li IWS et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol 2010; 82:1-7.
71. Xiao H, Lu S, Ou Q, Chen Y, Huang S. Hospitalized patients with novel influenza A (H1N1) virus infection: Shanghai, June - July 2009. Chin Med J 2010; 123:401-405.
72. Redelman-Sidi G, Sepkowitz KA, Huang CK et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60:257-263.
73. Tsalik EL, Hendershot EF, Sangvai DG et al. Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. J Clin Virol 2010; 47:286-288.
74. Komiya N, Gu Y, Kamiya H et al. Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. Euro Surveill. 2009;14.
75. Grijalva-Otero I, Talavera JO, Solorzano-Santos F et al. Critical analysis of deaths due to atypical pneumonia during the onset of the influenza A (H1N1) virus epidemic. Arch Med Res 2009; 40:662-668.
76. Kwan-Gett TS, Baer A, Duchin JS. Spring 2009 H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prep 2009; 3(Suppl. 2):S109-S116.
77. Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-1525.
78. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27-35.
79. Creanga AA, Johnson TF, Graitcer SB et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115:717-726.
80. Denholm JT, Gordon CL, Johnson PD et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 2010; 192:84-86.
81. Perez-Padilla R, de La Rosa-Zamboni D, Ponce De Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-689.
82. Miller RR, Markewitz BA, Rolfs RT et al. Clinical findings and demographic factors associated with ICU admission in Utah due to novel 2009 influenza A(H1N1) infection. Chest 2010; 137:752-758.
83. Chien Y-S, Su C-P, Tsai H-T et al. Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. J Infect 2010; 60:168-174.
84. Rello J, Rodríguez A, Ibañez P et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009; 13:R148.
85. Domínguez-Cherit G, Lapinsky SE, Macias AE et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-1887.
86. Donaldson LJ, Rutter PD, Ellis BM et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009; 339:b5213.
87. Lee EH, Wu C, Lee EU et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:1498-1504.
88. Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896-1902.
89. Dill CE, Favata MA. Novel influenza A (H1N1) outbreak on board a US navy vessel. Disaster Med Public Health Prep 2009; 3(Suppl. 2):S117-S120.
90. Kimberlin DW, Escude J, Gantner J et al. Targeted antiviral prophylaxis with oseltamivir in a summer camp setting. Arch Pediatr Adolesc Med 2010; 164:323-327.
91. Odaira F, Takahashi H, Toyokawa T et al. Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, May-June 2009. Euro Surveill 2009; 14:pii: 19320.
92. Pebody RG, Harris R, Kafatos G et al. Use of Antiviral Drugs to Reduce Household Transmission of pandemic (H1N1) 2009, United Kingdom. Emerg Infect Dis 2011; 17:990-999.
93. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ 2011; 342:d3214.
94. Bloom-Feshbach K, Simonsen L, Viboud C et al. Natality decline and miscarriages associated with the 1918 influenza pandemic: the Scandinavian and United States experiences. J Infect Dis 2011; 204:1157-1164.
95. Strong M, Burrows J, Redgrave P. A/H1N1 pandemic. Oseltamivir's adverse events. BMJ 2009; 339:b3249.
96. Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill 2009; 14:19285.
97. Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol 2011; 1:254-262.
98. Conway JM, Tuite AR, Fisman DN et al. Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. BMC Public Health 2011; 11:932.
99. Hsu J, Santesso N, Mustafa R et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512-524.